CAR T-cell therapies offer curative potential for aggressive cancers but face challenges of high cost, complex logistics, and small patient volumes. In 2024, sales reached $2.8B across seven FDA-approved products, with list prices around $484K. IQVIA’s integrated data approach combines primary research with secondary claims and monitoring to map the patient journey—from diagnosis and referral to treatment and follow-up. Insights reveal that only 1–5% of eligible patients receive therapy, with barriers including patient refusal, ineligibility, and cost. Expanding certified treatment centers and tracking long-term care are essential to improving outcomes.

Join for free to read